Strategies for Ensuring Biomanufacturing Resilience for Biologics

by Oliver Prince, Ph.D. | August 31, 2023

Resilience-Biomanufacturing-Promo-Banner_1200x627_M

There is consensus among the global health community that long-term collaboration in resilient biomanufacturing capacity and supply chains is needed to ensure the reliable delivery of health technologies such as vaccines, even during crisis conditions.

This paper highlights strategies that are essential to achieving this outcome, drawn from the experience of our company during the global pandemic response and looking forward to how governments and the private sector, including profit and not-for-profit private health actors, can most effectively work together to deliver healthcare post-pandemic. The strategies focus on vaccines, monoclonal antibodies, and new modalities manufactured by biotechnology companies and institutes.

Learn more here.

[molongui_author_box]

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

Covid-19 Impact on Bioprocessing: PART 1 Accelerating Trends

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 2 Fears to Be Addressed due to Covid-19

The views and opinions expressed in this blog / article are those of the authors and do not…

Covid-19 Impact on Bioprocessing: PART 3 Long-term Changes Resulting from the Pandemic

The views and opinions expressed in this blog / article are those of the authors and do not…

Scroll to Top